TAI'AN, China, June 8 /PRNewswire-Asia-FirstCall/ -- China Biologic Products, Inc. (Nasdaq: CBPO) ("China Biologic," or the "Company"), a leading plasma-based biopharmaceutical company in China, today announced that it will present at the Jeffries 2010 Global Life Sciences Conference, which is being held June 8 - 11, 2010, at the Grand Hyatt in New York City.
China Biologic's management is scheduled to present on Friday, June 11, 2010, at 11:00 am ET. Management will be available to meet with institutional investors throughout the day. Please contact Jeffries' institutional sales representative for additional details.
About China Biologic Products, Inc.
China Biologic Products, Inc. (the "Company"), through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co. Ltd. and Guiyang Dalin Biologic Technologies Co., Ltd, and its equity investment in Xi'an Huitian Blood Products Co., Ltd., is currently the largest non-state-owned plasma-based biopharmaceutical company in China. The Company is a fully integrated biologic products company with plasma collection, production and manufacturing, research and development, and commercial operations. The Company's plasma-based biopharmaceutical products are irreplaceable during medical emergencies, and are used for the prevention and treatment of various diseases. The Company sells its products to hospitals and other healthcare facilities in China.
For more information, please contact:
Company Contact:
Mr. Y. Tristan Kuo
Chief Financial Officer
China Biologic Products, Inc.
Tel: +86-538-6202206
Email: IR@chinabiologic.com
www.chinabiologic.com
Investor Relations Contact:
Ms. Lei Huang, Account Manager
CCG Investor Relations
Phone: +1-646-833-3417
Email: lei.huang@ccgir.com
www.ccgirasia.com
Mr. Crocker Coulson, President
Phone: +1-646-213-1915
Email: crocker.coulson@ccgir.com
